

Launch of a Capital Increase with Shareholders' Preferential Subscription Rights (PSR)

- Capital increase of €4.49 million with PSR through the issuance of new shares at a ratio of 1 new share for 7 PSRs (which may be increased to €5.16 million in the event of the full exercise of the 15% Extension Clause).
- Subscription price per new share: €0.250, representing a 29.2% discount to IMPLANET's closing share price on October 8, 2025 (€0.353) and a 26.5% discount to the theoretical ex-rights price.
- Detachment of PSRs on October 14, 2025, with the subscription period open from October 16 to October 29, 2025.
- Subscription and guarantee commitments totaling €4.49 million, already representing 100% of the planned issuance.

**IMPLANET's management will host a webinar
on Tuesday, October 14, 2025, at 6:00 pm (CEST)**
[REGISTER HERE](#)

Bordeaux, Boston, le October 9, 2025 – 08:00 am CEST - IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME) (the "**Company**"), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of advanced medical equipment, today announced the launch of a cash capital increase with shareholders' preferential subscription rights ("**PSR**") (the "**Capital Increase**") in the amount of €4,485,747.25, through the issuance of 17,942,989 new shares (the "**New Shares**") at a unit price of €0.250, representing a 29.2% discount to the closing price on October 8, 2025 (€0.353), the date on which the issue price was set by the Board of Directors.

The total amount of the offering may be increased to a maximum of €5,158,609.25, corresponding to the issuance of up to 20,634,437 additional New Shares, in the event that the 15% extension clause (the "**Extension Clause**") is fully exercised.

The net proceeds from this Capital Increase will enable IMPLANET to further accelerate the deployment of its strategic roadmap and will be used as follows:

- Approximately 44% to strengthen the Company's presence in the United States:
 - Reinforce the resources and commercial capabilities available to the historical team through the recruitment of an experienced sales force;
 - Equip the Company with the necessary tools to accelerate the rollout of JAZZ® and the co-developed products with Sanyou Medical;
 - Strengthen the Company's direct approach by expanding its scientific team of key opinion leaders.

For translation purposes only - This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for securities in France or in any country other than France. This press release must not be published, transmitted, or distributed, directly or indirectly, in or into the United States of America, Canada, Australia, or Japan.

- Approximately 30% will be allocated to the deployment of co-developed products in strategic geographic regions:
 - Support the commercial rollout of JSS and other Sanyou product ranges in France, the United States, and internationally.
- Approximately 16% will be dedicated to strengthening market momentum and expanding the product offering:
 - Position Implanet as the exclusive distributor in Europe and the United States for the Sanyou Medical group's assistance technologies and those of its partners;
 - Launch the SMTP Quntas range (ultrasonic scalpels with aspiration), marking the brand's entry into the revision and tumor surgery markets.
- Finally, approximately 10% will be used to finalize the registration of existing products under the European Medical Device Regulation (MDR) and to obtain FDA 510(k) clearances.

Once completed, this Capital Increase will provide the Company with more than 12 months of financial visibility, as the offering is fully guaranteed (100%).

TERMS AND CONDITIONS OF THE NEW SHARE ISSUE

Share Capital Before the Capital Increase

At the date of the launch of the Capital Increase, IMPLANET's share capital is composed of 125,600,929 shares, all fully subscribed and paid up, with a par value of €0.01 per share, admitted to trading on Euronext Growth Paris.

Share Identification Codes

Name: IMPLANET
 ISIN Code: FR0013470168
 Ticker Symbol: ALIMP
 Listing Venue: Euronext Growth Paris

Nature of the Transaction

The capital raising proposed by the Company consists of a capital increase through the issuance of new ordinary shares ("New Shares") with maintenance of shareholders' preferential subscription rights (PSRs).

The transaction will involve the issuance of 17,942,989 New Shares (excluding the potential exercise of the Extension Clause) at a subscription price of €0.250 per New Share, on the basis of 1 New Share for every 7 existing shares held (7 PSRs will entitle the holder to subscribe for 1 New Share).

This represents a gross offering amount of €4,485,747.25 (corresponding to a nominal capital increase of €179,429.89, with an issue premium of €4,306,317.36) and a net proceeds estimate of €4.0 million.

This amount may be increased to €5,158,609.25 (corresponding to a nominal capital increase of €206,344.37, with an issue premium of €4,952,264.88) in the event that the Extension Clause, representing up to 15% of the initial amount, is fully exercised (i.e., a maximum of 20,634,437 New Shares) for net proceeds of €4.6 million.

Legal Framework of the Offering

Acting under the delegations granted by the 11th and 15th resolutions adopted by the Combined General Meeting of Shareholders held on April 11, 2025, the Board of Directors of IMPLANET, at its meeting on October 8, 2025, decided to launch a capital increase with maintenance of shareholders' preferential subscription rights.

Extension Clause

Depending on the level of demand, Implanet reserves the right to exercise the Extension Clause, up to a maximum of 15% of the initial offering amount, increasing the gross proceeds from €4,485,747.25 to €5,158,609.25, in order to satisfy all or part of additional reducible subscription orders.

Accordingly, the initial number of 17,942,989 New Shares may be increased by up to 2,691,448 additional New Shares, bringing the total maximum number of New Shares to be issued to 20,634,437

Subscription Price

The subscription price has been set at €0.250 per New Share (comprising a €0.01 nominal value and a €0.24 issue premium), representing a 29.2% discount to IMPLANET's closing share price on October 8, 2025 (€0.353), the date on which the issue price was set by the Board of Directors, and a 26.5% discount to the theoretical ex-rights price of the IMPLANET share.

Discount Relative to the Issue Price of €0.250 per Share:

	In €	Discount (-) / Premium (+)
Last closing price on October 8, 2025	0.353	-29.2%
20-day volume-weighted average price	0.354	-29.5%
60-day volume-weighted average price	0.274	-8.8%

Subscription Period for the New Shares

The subscription period for the New Shares will be open from October 16, 2025, to October 29, 2025 (inclusive).

Preferential Subscription Rights on an Irreducible Basis

Subscription for the New Shares is reserved, by preference, for (i) holders of existing shares recorded in their securities accounts at the close of trading on October 15, 2025, who will receive one preferential subscription right (PSR) per share held, and (ii) purchasers of PSRs.

Holders of PSRs may subscribe on an irreducible basis, at a rate of 1 New Share for every 7 existing shares held, i.e., 7 PSRs entitle the holder to subscribe for 1 New Share, at a unit price of €0.25 per share, with no account taken of fractional entitlements.

PSRs may only be exercised in multiples corresponding to an integer number of New Shares. Shareholders or purchasers of PSRs who do not hold, under the irreducible subscription rights, a sufficient number of existing shares or PSRs to obtain a whole number of New Shares will need to buy or sell the necessary number of PSRs on the market to reach a multiple that allows the subscription of a whole number of New Shares.

Preferential Subscription Rights on a Reducible Basis

A preferential subscription right on a reducible basis is granted to shareholders, allowing them to subscribe for additional New Shares proportionally to their rights and within the limits of their requests.

At the same time as they submit their irreducible subscriptions, shareholders or holders of PSRs may subscribe on a reducible basis for as many additional New Shares as they wish, beyond those resulting from the exercise of their PSRs on an irreducible basis.

Any New Shares not subscribed for on an irreducible basis will be allocated and distributed to subscribers on a reducible basis. Reducible subscription orders will be filled within the limits of the requests and in proportion to the number of existing shares whose rights were used in support of their irreducible subscription, with no allocation of fractional New Shares.

Implanet reserves the right to exercise the Extension Clause, up to 15% of the initial offering amount, in order to satisfy all or part of the reducible subscription requests.

If a single subscriber submits multiple separate subscriptions, the number of New Shares allocated to them on a reducible basis will only be calculated on the total number of PSRs held, provided that they make a specific written request to this effect no later than the subscription closing date.

This request must be attached to one of the subscriptions and must provide all necessary details for the aggregation of rights, including the number of subscriptions filed and the authorized financial intermediaries with whom such subscriptions were submitted.

Subscriptions made in the name of different subscribers may not be combined to obtain New Shares on a reducible basis.

A notice published by Euronext will, where applicable, disclose the allocation scale for reducible subscriptions.

Funds paid for reducible subscriptions that remain available after the allocation process will be refunded without interest to the subscribers by the financial intermediaries that received them.

It is specified that the Company does not hold any of its own shares as of the date of this press release.

Exercise of Preferential Subscription Rights

To exercise their Preferential Subscription Rights (PSRs), holders must submit a request to their authorized financial intermediary at any time during the subscription period, from October 16, 2025, to October 29, 2025 (inclusive), and pay the corresponding subscription price¹.

Each subscription must be accompanied by payment of the subscription price, either in cash or by offsetting liquid and due receivables against the Company. Subscriptions that are not fully paid up will be automatically cancelled by law, without the need for formal notice.

PSRs must be exercised by their holders before the end of the subscription period, otherwise they will automatically lapse.

PSRs will be tradable from October 14, 2025, to October 27, 2025 (inclusive), under the same conditions as existing shares.

¹ The custodian account holder of a PSR holder may shorten the deadlines (date and time limits) for exercising preferential subscription rights. We remind investors that custodians are required to inform them through securities operations, and investors are therefore encouraged to contact their custodian for further details.

The transferor of the PSR shall thereby be divested in favor of the transferee, who, for the exercise of the preferential subscription right thus acquired, shall be substituted in all the rights and obligations of the holder of the existing share.

PSRs not exercised by the end of the subscription period shall automatically lapse.

Listing of the Preferential Subscription Rights (PSRs)

At the close of trading on October 13, 2025, 1 PSR will be credited for each share held in IMPLANET shareholders' securities accounts (for a total of 125,600,929 PSRs issued). Each shareholder holding 7 PSRs (or multiples thereof) may subscribe for 1 New Share (or multiples thereof) at a subscription price of €0.250 per share.

The PSRs will be listed and traded on Euronext Growth under ISIN code FR0014013496, from October 14, 2025, to October 27, 2025 (inclusive).

If PSRs are neither subscribed nor sold before the end of the subscription period, they will automatically lapse and become worthless.

Theoretical Value of the Preferential Subscription Right (PSR) and of the Ex-Rights Share

Based on the closing share price of €0.353 on October 8, 2025, the theoretical value of the PSR is €0.013. This corresponds to a theoretical value of the IMPLANET share ex-rights (the "Theoretical Ex-Rights Share Value") of €0.340.

The subscription price of €0.25 per New Share therefore represents a discount of 26.5% compared with the Theoretical Ex-Rights Share Value on the same date.

These values are for illustrative purposes only and do not predict the actual market value of either the preferential subscription right during its trading period or the ex-rights share value as observed in the market.

Subscription on a Free Basis

Any individual or legal entity, whether or not they hold Preferential Subscription Rights (PSRs), may subscribe to the Capital Increase on a free basis. Persons wishing to subscribe on a free basis must submit their subscription request to their authorized financial intermediary at any time during the subscription period and pay the corresponding subscription price. In accordance with Article L.225-134 of the French Commercial Code, free subscriptions will only be taken into account if the irreducible and reducible subscriptions do not absorb the entire Capital Increase, it being specified that the Board of Directors has delegated to the Chief Executive Officer the authority to freely allocate any unsubscribed New Shares, in whole or in part, among the persons (shareholders or third parties) of his choosing who have submitted free subscription requests.

Reallocation by the Chief Executive Officer, Acting on Delegation from the Board of Directors, of Unsubscribed New Shares Following Irreducible and, Where Applicable, Reducible Subscriptions of PSRs

If the subscriptions for New Shares do not cover the entire issue, the Chief Executive Officer, acting on delegation from the Board of Directors, may make use, in whole or in part, of the powers granted under Article L.225-134 of the French Commercial Code, and in such order as he deems appropriate.

At the end of the subscription period, the Chief Executive Officer, acting on delegation from the Board of Directors and pursuant to the authorization granted by the Combined General Meeting of April 11, 2025 (11th resolution), will record the amount of the Capital Increase that has not been subscribed for on an irreducible basis and, where applicable, on a reducible basis.

He will then have full discretion to allocate any remaining unsubscribed shares among investors who have expressed interest, in accordance with the provisions of Article L.225-134 of the French Commercial Code.

It should be noted that the Company has received subscription commitments and subscription guarantee commitments for a total amount of €4,485,747.25, representing 100% of the amount of the Capital Increase (excluding the Extension Clause), thereby fully securing the completion of the transaction. Details of these guarantee commitments are provided in the section “Other Commitments” below.

The subscription guarantee commitments will be triggered in the event that the total subscriptions for the New Shares (irreducible, reducible, and free basis subscriptions) represent less than 100% of the Capital Increase (excluding the Extension Clause). In such a case, they will be applied up to the amount necessary to reach 100% of the Capital Increase (excluding the Extension Clause).

Limitation of the Capital Increase Amount

In accordance with the provisions of Article L.225-134 of the French Commercial Code, and pursuant to the 11th resolution of the Combined General Meeting of Shareholders held on April 11, 2025, and the decision of the Board of Directors dated October 8, 2025, if the irreducible and reducible subscriptions do not absorb the entire issue, the Chief Executive Officer, acting under delegation from the Board of Directors, may (i) limit the amount of the transaction to the subscriptions received, provided that these represent at least three-quarters (75%) of the decided Capital Increase; (ii) freely allocate, at his sole discretion, all or part of the unsubscribed shares, in particular to investors (shareholders or non-shareholders) who have expressed interest in subscribing on a free basis; or (iii) offer the remaining shares to the public.

These options may be exercised alternatively or cumulatively.

However, Implanet has received subscription commitments and guarantee commitments totaling €4,485,747.25, representing 100% of the Capital Increase (excluding the Extension Clause) (an amount exceeding the threshold required under Article L.225-134 of the French Commercial Code) (see section “Subscription Commitments”).

Guarantee

This offering is not subject to an underwriting guarantee within the meaning of Article L.225-145 of the French Commercial Code. As a result, trading in the new shares will begin only after the settlement-delivery operations have been completed and the depositary certificate has been issued.

Subscription Commitments

Sanyou (HK) International Medical Holding Co., Limited (“Sanyou”), which holds 93,176,946 IMPLANET shares, representing 74.18% of IMPLANET’s share capital, will not participate in the Capital Increase.

However, under subscription commitments signed on September 26 and 28, 2025, certain corporate officers of IMPLANET and Shanghai Sanyou Medical Co., Ltd, who do not currently hold any shares in the Company, have irrevocably undertaken to subscribe to the Capital Increase for a total amount of €2,099,985, representing 46.81% of the Capital Increase (excluding the exercise of the Extension Clause), as detailed below:

Name	Position	Commitment (€)
Mr. Nong XU	Chief Executive Officer, Shanghai Sanyou Medical	1,000,000
Mr. Michael Mingyan LIU	Chairman of IMPLANET's Board of Directors; Chairman and Deputy Chief Executive Officer of Shanghai Sanyou Medical	300,000
Mr. David FAN	Director of IMPLANET; Chairman of Sanyou (HK) International Medical Holding; Chairman and Deputy Chief Executive Officer of Shanghai Sanyou Medical	300,000
Mr. Qun CAO	Chairman, SMTP	249,985
Mrs Xiaoyi ZHENG	Director, Shanghai Sanyou Medical	250,000
Total		2,099,985

The above-mentioned individuals have declared, where applicable, that they are acting in concert with Sanyou.

The Company is not aware of the intentions of its other shareholders.

Other Commitments

The Company has also received guarantee commitments from third-party investors (the “**Guarantors**”) for a total amount of €2.39 million. The details of the Guarantors are provided in the table below:

Names	Guarantee Commitment (€)
Nice&Green	380,762
Friedland Gestion	380,000
Maitice Gestion	380,000
Gestys	470,000
Treecap B.V.	225,000
Vesta Capital	550,000
Total	2,385,762

These commitments will be triggered if the total subscriptions for the New Shares (irreducible, reducible, and free basis subscriptions) represent less than 100% of the Capital Increase (excluding the Extension Clause), and up to the total amount necessary to reach 100% of the Capital Increase (excluding the Extension Clause).

All Guarantors will receive a commission equal to 10% of the amount of their respective commitments, regardless of the number of shares ultimately allocated to them.

In the event of a partial exercise of these guarantee subscription commitments, the amount to be subscribed by the Guarantors will be allocated among them pro rata to the respective amount of their maximum commitment.

In total, the subscription commitments and subscription guarantee commitments represent €4,485,747.25, corresponding to 100% of the Capital Increase (excluding the Extension Clause).

Authorized Intermediary — Payment of Subscriptions

Subscriptions for the New Shares and the corresponding payments by subscribers whose shares are held in administered registered form or bearer form will be accepted up to and including the closing date of the subscription period by their authorized financial intermediaries, acting in their name and on their behalf.

Subscriptions and payments by subscribers whose shares are held in pure registered form will be accepted free of charge up to and including the closing date of the subscription period by UPTEVIA – 90-110 Esplanade du Général de Gaulle, 92931 Paris La Défense Cedex.

The New Shares must be fully paid up at the time of subscription, either in cash and/or by offsetting receivables, for the total amount of the par value and issue premium. It is specified that the amount corresponding to the issue premium will be recorded as a liability under the “Share Premium” account, to which both existing and new shareholders will have rights.

Funds paid in support of subscriptions will be centralized by UPTEVIA – 90-110 Esplanade du Général de Gaulle, 92931 Paris La Défense Cedex, which will be responsible for issuing the certificate of deposit of funds, confirming the completion of the capital increase and the issuance of the New Shares.

Subscriptions for which payments have not been made in full will be automatically cancelled by operation of law, without the need for formal notice.

Settlement and Delivery of the New Shares

According to the indicative timetable of the offering, the settlement and delivery date for the New Shares is scheduled for November 5, 2025.

CHARACTERISTICS OF THE NEW SHARES

Entitlement

The New Shares will carry current dividend rights and will be assimilated to the Company’s existing shares, entitling their holders to any distributions decided by the Company from that date onward.

Listing of the New Shares

The New Shares will be the subject of an application for admission to trading on the Euronext Growth Paris market on November 5, 2025. They will be immediately fungible with the Company’s existing shares already traded on Euronext Growth Paris and will be tradable from that date on the same trading line under the same ISIN code FR0013470168 - ticker: ALIMP.

DILUTION

Impact of the Offering on Consolidated Net Assets per Share

The impact of the issuance on the Company's share of consolidated equity per share (calculations based on consolidated equity attributable to the Group as reported in the interim financial statements as of June 30, 2025, excluding interim losses, and on a total of 125,600,929 shares constituting the Company's share capital as of this date) would be as follows:

Consolidated Equity per Share (in euros)		
	Undiluted Base*	Fully Diluted Base (assuming exercise of all existing instruments)**
Before issuance of the New Shares under this Capital Increase	-0.011	0.000
After issuance of 17,942,989 New Shares under this Capital Increase	0.022	0.031
After issuance of 20,634,437 New Shares under this Capital Increase (in case of full exercise of the 15% Extension Clause)	0.026	0.035

*: The amount of consolidated equity as of June 30, 2025, adjusted for capital increases completed between July 1, 2025, and the date hereof, and excluding interim losses, amounts to -€1,358 thousand.

** : Assuming the exercise of all outstanding warrants (BSA), founder share warrants (BSPCE), and stock options, whether exercisable or not, i.e., 1,375,354 BSPCE, 522,500 stock options, 990,000 BSA, and 728,805 free shares, the exercise of which would result in the creation of 1,971,235 new shares.

Impact of the Offering on Shareholder Ownership

Participation de l'actionnaire (en%)		
	Undiluted Base	Fully Diluted Base (assuming exercise of all existing instruments)**
Before issuance of the New Shares under this Capital Increase	1.000	0.985
After issuance of 17,942,989 New Shares under this Capital Increase	0.875	0.863
After issuance of 20,634,437 New Shares under this Capital Increase (in case of full exercise of the 15% Extension Clause)	0.859	0.847

** : Assuming the exercise of all outstanding warrants (BSA), founder share warrants (BSPCE), and stock options, whether exercisable or not, i.e., 1,375,354 BSPCE, 522,500 stock options, 990,000 BSA, and 728,805 free shares, the exercise of which would result in the creation of 1,971,235 new shares.

Impact of the Capital Increase on Shareholding Structure

The following table shows the breakdown of the Company's share capital before and after the completion of the Capital Increase, assuming 100% of the offering is subscribed² :

	Before the Transaction		After the Transaction	
	Number of Shares	% of Share Capital and Voting Rights (undiluted)	Number of Shares	% of Share Capital and Voting Rights (undiluted)
Sanyou (HK) International Medical Holding CO Limited	93,176,946	74.18%	93,176,946	64.91%
Sanyou Corporate Officers	0	-	8,399,940	5.85%
Total Sanyou concerted group	93,176,946	74.18%	101,576,886	70.76%
Guarantors	0	-	9,543,049	6.65%
Management and employees	1,486,696	1.18%	1,486,696	1.04%
Other individual shareholders	602,555	0.48%	602,555	0.42%
Free float	30,334,732	24.15%	30,334,732	21.13%
Total	125,600,929	100.00%	143,543,918	100.00%

Suspension of Rights to the Allocation of New Shares

Holders of stock subscription options, founder share warrants (BSPCE), and share warrants (BSA) granted or issued by the Company have been informed that their right to receive new shares of the Company has been suspended as of October 1, 2025 (00:01 a.m., Paris time) for a maximum period of three months, unless this period is shortened.

The resumption date of their right to receive new shares of the Company will be specified in a notice sent to all holders at a later date.

The rights of holders of stock subscription options, BSPCEs, and BSAs who did not exercise their right to receive new shares before October 1, 2025 (00:00 a.m., Paris time) will be preserved in accordance with legal and regulatory provisions.

Subscription Procedures

You hold Preferential Subscription Rights (PSRs) attached to your IMPLANET shares, which entitle you to subscribe by priority to the New Shares at a ratio of 1 New Share for every 7 PSRs (1 existing share entitles you to 1 PSR).

If you hold an exact and sufficient number of existing shares, you may subscribe through your PSRs for an integer number of New Shares (for example, if you hold 7 IMPLANET shares, you may subscribe by priority to 1 New Share).

If you do not hold a sufficient number of existing shares to obtain an integer number of New Shares, you may buy or sell PSRs in order to reach the ratio that allows you to subscribe for a whole number of New Shares (1 New Share for every 7 PSRs).

² Refer to the note above.

In addition, beyond the subscriptions made through the PSRs you hold, you may also subscribe on a free basis up to and including October 29, 2025 (however, your free subscription will only be considered if the offering has not already been fully subscribed by holders of PSRs).

Each subscription must be accompanied by payment of the subscription price.

INDICATIVE TIMETABLE OF THE TRANSACTION

October 8, 2025	Decision of the Board of Directors to launch the Capital Increase
October 9, 2025	Publication of the press release announcing the Capital Increase
October 10, 2025	Publication by Euronext of the notice of issuance
October 13, 2025	Record date at the close of which holders of existing shares registered in their securities accounts will be allocated Preferential Subscription Rights (PSRs)
October 14, 2025 (inclusive)	Detachment (before market opening) of PSRs Admission to trading and start of trading of PSRs
October 16, 2025 (inclusive)	Opening of the subscription period for the New Shares Start of the PSR exercise period
October 27, 2025 (inclusive)	End of PSR trading period
October 29, 2025 (inclusive)	Closing of the subscription period for the New Shares Closing of the PSR exercise period
November 3, 2025	Decision by the Chief Executive Officer to issue the New Shares and, where applicable, to limit or reallocate the Capital Increase or exercise the Extension Clause Publication of the press release announcing the results of the transaction Publication by Euronext of the notice of admission
November 5, 2025	Settlement and delivery of the New Shares

Prospectus

Pursuant to the provisions of Articles L.411-2-1, 1° of the French Monetary and Financial Code and Article 211-2 of the General Regulations of the French Financial Markets Authority (Autorité des Marchés Financiers – AMF), this offering will not give rise to a Prospectus approved by the AMF, as the total offering amount is below €8,000,000, it being specified that no similar offering has been made by the Company during the past twelve months.

A notice to shareholders relating to this transaction will be published on October 10, 2025, in the Bulletin des Annonces Légales et Obligatoires (BALO).

Risk Factors

The Company draws attention to the other risk factors relating to the Company and its business, which are described in Chapter 4 “Risk Factors” of the Company’s 2017 Registration Document filed with the AMF on

April 16, 2018, under number D.18-0337, as well as in the annual financial report as of December 31, 2024, and the interim financial report as of June 30, 2025.

The main additional risk factors relating to the forthcoming Capital Increase are as follows:

- The market for the preferential subscription rights (PSRs) may offer limited liquidity and be subject to high volatility;
- Shareholders who do not exercise their PSRs will see their ownership in the Company diluted. The potential exercise of the Extension Clause could result in additional dilution;
- The market price of the Company's shares could fluctuate and fall below the subscription price of the shares issued upon exercise of the PSRs;
- In the event of a decline in the market price of the Company's shares, the PSRs may lose their value;
- The volatility and liquidity of the Company's shares could fluctuate significantly;
- Sales of the Company's shares on the market could occur and have an adverse impact on the Company's share price;
- Shareholders may experience significant dilution as a result of future capital increases.

Advisors to the Transaction

Atout Capital

Financial Advisor

Bird & Bird

Legal Advisor

Prochains évènements financiers

- **Webinar** on October 14, 2025, at 6:00 pm (CEST)
- **Full-year 2025 revenue**, January 13, 2026, after market close

About Sanyou Medical

Founded in 2005, Shanghai Sanyou Medical Co., Ltd. is a company dedicated to the research, development, manufacturing, and sale of innovative and independent orthopedic products.

Shanghai Sanyou's main products include spinal and trauma implants. The company is one of the few in China capable of delivering original innovations based on clinical needs in the field of spinal implants.

The company has established a comprehensive product development system and is equipped with state-of-the-art R&D facilities and a project management system designed to ensure the advancement, efficiency, and reliability of its products. As of the end of January 2021, Shanghai Sanyou Medical had obtained 22 Class III medical device registration certificates and held 131 patents, including 28 Chinese invention patents, 98 Chinese utility model patents, 1 U.S. utility patent, 1 Australian invention patent, 1 Japanese invention patent, 1 German utility model patent, and 1 Chinese design patent.

About IMPLANET

IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ®), complemented by the product range of thoraco-lumbar screws, cages, and cervical plates, acquired through Orthopaedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological, and financial partnership with Sanyou Medical, China's second-largest medical device manufacturer. As part of this strategic agreement, IMPLANET developed in 2024 the Jazz Spinal System™ hybrid fixation system, a unique new range featuring a comprehensive pedicle screw solution, combined with the market's most advanced braided implant technology, JAZZ®. IMPLANET's orthopedic platform is built on the traceability of its products. Protected by four families of international patents, JAZZ® has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA), CE marking in Europe, and ANVISA approval in Brazil. IMPLANET employs 46 people and generated €9.4 million in consolidated revenue in 2024. Based near Bordeaux, France, IMPLANET has operated a U.S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris.

For more information, visit www.implanet.com.

Contacts

IMPLANET

Ludovic Lastennet, CEO
David Dieumegard, CFO
Tel. : 05 57 99 55 55
investors@implanet.com

NEWCAP

Investor Relations
Mathilde Bohin
Tel. : 01 44 71 94 94
implanet@newcap.eu

NEWCAP

Media Relations
Arthur Rouillé
Tel. : 01 44 71 94 94
implanet@newcap.eu

Disclaimer

This press release contains forward-looking statements relating to IMPLANET and its business activities. IMPLANET believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the forecasts expressed in these forward-looking statements will be achieved, as they are subject to various risks and uncertainties, including those described in IMPLANET's Reference Document filed with the French Financial Markets Authority (Autorité des Marchés Financiers - AMF) on April 16, 2018, under number D.18-0337, as well as in the annual financial report as of December 31, 2024, and the interim financial report as of June 30, 2025, available on the Company's website (www.implanet-invest.com). These forward-looking statements are also subject to risks unknown to IMPLANET or risks that IMPLANET does not currently consider material. The realization of some or all of these risks could cause the actual results, financial conditions, performance, or achievements of IMPLANET to differ materially from those expressed in these forward-looking statements. IMPLANET undertakes no obligation to update the information or forward-looking statements contained herein, except as required under applicable regulations, including Articles 223-1 et seq. of the General Regulation of the AMF.

This press release does not constitute an offer to sell or a solicitation of an offer to purchase any securities, and there will be no sale of ordinary shares in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or approval under the securities laws of such jurisdiction.

The distribution of this press release may be subject to specific legal or regulatory restrictions in certain countries. Persons in possession of this document are required to inform themselves about and comply with any such local restrictions.

This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (as amended, the "Prospectus Regulation").

With respect to the Member States of the European Economic Area (other than France) (the "Member States"), no action has been or will be taken to permit a public offering of securities requiring the publication of a prospectus in any of these Member States. Consequently, the securities may not and will not be offered in any of these Member States (other than France) except in accordance with the exemptions provided for in Article 1(4) of the Prospectus Regulation, or in other cases not requiring IMPLANET to publish a prospectus under the Prospectus Regulation and/or applicable local regulations. This press release does not constitute a public offering of securities in the United Kingdom.

This press release may not be published, distributed, or disseminated in the United States (including its territories and possessions). It does not constitute an offer or solicitation to purchase, sell, or subscribe for securities in the United States. The securities mentioned herein have not been registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), or under any state or other securities laws in the United States, and may not be offered or sold in the United States absent registration under the Securities Act or pursuant to an applicable exemption therefrom. IMPLANET does not intend to register any portion of the offering in the United States under the Securities Act, nor to conduct a public offering in the United States.

This press release may not be distributed, directly or indirectly, in or into the United States, Canada, Australia, or Japan.

Finally, this press release may be drafted in both French and English. In the event of any differences between the two versions, the French version shall prevail.